Tracon begins dosing in Phase Ib trial of lung cancer drug candidate TRC105
US-based Tracon Pharmaceuticals has begun a Phase Ib clinical trial of TRC105, a clinical stage antibody to endoglin, in combination with Avastin (bevacizumab), and carboplatin and paclitaxel chemotherapy in patients with non-small cell lung cancer (…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals